Open AccessCerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
Author(s) -
Vandewynckel YvesPaul,
Geerts Anja,
Verhelst Xavier,
Van Vlierberghe Hans
Publication year - 2014
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.34
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , stroke (engine) , oncology , gastroenterology , engineering , mechanical engineering
Key Clinical Message Sorafenib is the standard treatment of hepatocellular carcinoma ( HCC ). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26‐year‐old man with fibrolamellar HCC , who had a cerebrovascular accident ( CVA ) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and CVA in low cardiovascular risk patients.